Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Kimberly Blackwell
|
| gptkbp:clinicalTrialPhase |
oncology
|
| gptkbp:collaboratesWith |
gptkb:Pfizer
gptkb:Novartis GlaxoSmithKline |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
cancer therapeutics
|
| gptkbp:foundedYear |
2014
|
| gptkbp:founder |
gptkb:Anthony_Sun
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:leadProductCandidate |
zanidatamab
ZN-c3 ZN-c5 |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ZNTL
|
| gptkbp:website |
https://www.zentalis.com/
|
| gptkbp:bfsParent |
gptkb:Boxer_Capital
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zentalis Pharmaceuticals
|